Condition: Homocystinuria Due to Cystathionine Beta-Synthase Deficiency · Sponsor: Aeglea Biotherapeutics
The purpose of this study is to evaluate the safety and tolerability of pegtarviliase in approximately 36 subjects with homocystinuria due to CBS deficiency.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UT Southwestern Medical Center | Dallas, Texas, United States | — |
| Westmead Hospital | Westmead, New South Wales, Australia | — |
| Royal Children's Hospital | Parkville, Victoria, Australia | — |
| Royal Melbourne Hospital | Parkville, Victoria, Australia | — |
| University Hospitals Birmingham NHS | Birmingham, United Kingdom | — |
| Great Ormond Street Hospital | London, United Kingdom | — |
| Guy's and St Thomas' Hospital NHS Foundation Trust | London, United Kingdom | — |
| University College London | London, United Kingdom | — |
| Salford Royal NHS Foundation Trust | Salford, United Kingdom | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05154890